Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
EGFR-TKI is good for the patients with EGFR-mutant non-small cell lung cancer.We design this clinical trail to confirm if the efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor(EGFR-TKI )(ICOTINIB) is better than whole brain irradiation for the patient with EGFR-mutant non-small cell lung cancer.
Epistemonikos ID: 7a591f2ff30e52912cf7b1d4bbdd34a3a0242721
First added on: May 11, 2024